![birthmarks-and-vascular-anomalies-center-2x](/-/media/project/ucsf/ucsf-bch/images/clinic/hero/birthmarks-and-vascular-anomalies-center-2x.jpg?h=1112&iar=0&w=2880&rev=64e908f164a04d8798f8922db4e75746&hash=4582DAEA1171BFD2443023EDFED097C0)
Birthmarks & Vascular Anomalies Center
Founded in 1991, UCSF's Pediatric Birthmarks and Vascular Anomalies Center was the first medical facility on the West Coast to specialize in the treatment of birthmarks and vascular anomalies. Since then, we have provided state-of-the-art, highly specialized care for all types of vascular birthmarks and anomalies, from the most common to the rare and complex.
Our team includes specialists from many different areas of medicine, including dermatology, otolaryngology, neuroradiology, orthopedics, plastic surgery and hematology-oncology. We care for patients with vascular growths, such as hemangiomas and other vascular tumors, and people with vascular malformations, including venous, lymphatic, arteriovenous and mixed malformations. We treat children with Klippel-Trenaunay syndrome as well as those diagnosed with lymphangioma, cavernous hemangioma, glomangioma, Proteus syndrome and other vascular anomalies.
During a visit, your child will see a dermatologist, plastic surgeon, interventional radiologist, dermatologic surgeon and otolaryngologist. This team will then meet to review the patient's medical history, physical exam, prior biopsies and imaging studies and decide on further recommendations for diagnosis and treatment. This process prevents the need for multiple initial doctor visits.
Our locations (1)
Our team
-
Erin Mathes
MD
Pediatric dermatologist -
Daniel Cooke
MD
Neurointerventional radiologist -
Patricia Cornett
MD
Hematologist -
Josephine A. Czechowicz
MD, FAAP
Pediatric otolaryngologist -
Debajyoti Datta
MD
Hematologist-oncologist -
Christopher Dowd
MD
Neurointerventional radiologist -
Rachelle Durand
DO
Pediatric interventional radiologist -
Ilona J. Frieden
MD
Pediatric dermatologist -
William Y. Hoffman
MD
Plastic and reconstructive surgeon -
Nicole W. Kittler
MD
Pediatric dermatologist -
Kazim Narsinh
MD
Neurointerventional radiologist -
Isaac M. Neuhaus
MD
Dermatologic surgeon -
Jason H. Pomerantz
MD
Plastic and reconstructive surgeon -
Kristina W. Rosbe
MD, FAAP, FACS
Pediatric otolaryngologist -
Lisa Sears
RN, BSN
Nurse -
Joseph Shieh
MD, PhD
Medical geneticist -
Kristin A. Shimano
MD
Pediatric hematologist-oncologist -
Beth Apsel Winger
MD, PhD
Pediatric hematologist-oncologist -
Rosanna Wustrack
MD
Orthopedic surgeon -
Melissa N. Zimel
MD
Orthopedic oncology surgeon
Awards & recognition
-
Ranked among the nation's best in 10 specialties
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
Support services
Clinical trials
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patien...
Response defined by achieving at least 20% reduction from baseline in the sum of target lesion volumes (1 to 3 lesions, assessed by MRI by a blinded independent review committee (BIRC)), provided that none of the individual target...
Recruiting
More about this studyA Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Seve...
The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT de...
Recruiting
More about this studyTreosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatmen...
The primary endpoint is the incidence of 1-year GVHD free, EFS (GEFS). An event is defined as death due to any cause, primary or secondary graft failure/rejection, or 2nd HCT whichever occurs first. Grade III-IV acute GVHD and chr...
Recruiting
More about this studyStudy to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thr...
Durable platelet response is defined as a proportion of participants able to achieve platelet counts at or above 50,000/μL for ≥ two-thirds of at least 8 non-missing weekly scheduled platelet measurements during the last 12 weeks ...
Recruiting
More about this studyFeeling at home
From bedside bingo to therapy dogs, we're here to help kids smile and feel more like themselves.
Visit Child Life services![](/-/media/project/ucsf/ucsf-bch/images/by-your-side-moment/bear/bys_footer_bear-neutral-2x.jpg?rev=81c20662c2cc4692822f4b8583f01035&hash=16F72F4D46749F5692334687A5843450)